Assembly Biosciences, Inc. is a biotechnology company developing therapeutics for serious viral and liver diseases. Its clinical-stage pipeline includes long-acting helicase-primase inhibitors for recurrent genital herpes, an orally bioavailable entry inhibitor for hepatitis delta virus, and a capsid assembly modulator for hepatitis B virus. The company also has a broad-spectrum non-nucleoside polymerase inhibitor in development for transplant-associated herpesviruses. In December 2025, Gilead Sciences exercised its option to exclusively license the company's helicase-primase inhibitor program, including candidates ABI-1179 and ABI-5366. Assembly Biosciences continues to advance its hepatitis delta virus candidate ABI-6250 toward Phase 2 trials and is evaluating partnering opportunities for its hepatitis B virus candidate ABI-4334. The company's research programs target multiple antiviral mechanisms to address unmet medical needs in virology and hepatology.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage assemblybio.com
Sector Healthcare IR page investor.assemblybio.com
Tags
antivirals, hepatitis, herpes, viral diseases, liver diseases, clinical-stage, helicase-primase inhibitors, capsid assembly modulators, entry inhibitors, polymerase inhibitors, ABI-1179, ABI-5366, ABI-6250, ABI-4334, ABI-7272, ABI-7423, Gilead Sciences
Press page —

Metrics

Valuation  
Market cap $ 406.916M
Market cap (USD) $ 406.916M
P/E 19.98
PEG —
P/BV 1.36
P/S 6.07
P/OCF -10.04
P/FCF -10.00
Dividend yield —
Turnover / mcap —
Returns  
ROE -5.1%
ROI -4.1%
ROIC -6.0%
Profit margin -8.5%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 38
Quality score -20.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Revenue 72.303M 28.52M 7.163M — 6.254M 79.105M 15.963M 14.804M — — — — — — — —
Net profit -6.122M -40.177M -61.228M -93.092M -129.855M -62.152M -97.634M -90.751M -42.809M -44.262M -28.454M -23.789M -19.404M -24.79M -34.345M -15.291M
Free cash flow -41.159M -51.145M 22.488M -84.565M -96.492M -63.427M -85.621M -65.298M 995.517K -35.028M -18.756M -15.123M -17.803M -21.383M -25.081M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Share price 34.01 15.78 0.82 1.3 2.33 6.05 20.46 22.62 45.25 12.15 7.51 7.86 — — — —
Price performance 12m 1.16 18.24 -0.37 -0.44 -0.61 -0.7 -0.1 -0.5 2.72 0.62 -0.04 — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 0.00 2.27M 2.43M 3.37M 1.23M 336,000 944,000 43,000 0.00 974,000
↳ YoY growth +6.9% +38.8% -63.5% -72.7% +181.0% -95.4% -100.0%
↳ 5y CAGR -16.1% -55.4% -4.6%
Lease liabilities (USD) — — 0.00 12.3M 10.1M 6.48M 3.47M 2.34M 3.09M 2.63M
Cash and deposits (USD) 28.6M 82M 41.5M 46.7M 59.4M 45.6M 52.4M 19.8M 38.3M 58.5M
Intangible assets (USD) 29M 29M — — — — — — — —
Right-of-use assets (USD) — — 13.8M 12M 9.13M 6.04M 3.2M 2.34M 3.07M 2.51M
Cash flow detail
Operating cash flow (USD) -34.9M 1.86M -65M -84.1M -63M -93.4M -84.5M 22.7M -51.1M -41.1M
Purchases of property, plant and equipment (USD) -146,329 -864,564 -340,000 -1.55M -470,000 -3.1M -102,000 -255,000 -28,000 -66,000
Change in receivables (cash effect) (USD) 0.00 -2.27M -156,000 -944,000 2.14M 894,000 -608,000 901,000 43,000 -974,000
Change in payables (cash effect) (USD) 1M -244,192 1.57M -1.96M 2.87M -1.94M -166,000 -2.03M 124,000 586,000
Income taxes paid (cash effect) (USD) — — — — — — — 0.00 -421,000 —
Share-based compensation (USD) 5.02M 8.6M 28.5M 20.6M 21.9M 5.24M 6.59M 5.12M 3.12M 4.68M
Operating cash flow before change in receivables (USD) -34.9M 4.13M -64.8M -83.1M -65.1M -94.3M -83.9M 21.8M -51.2M -40.1M
Free cash flow (OCF - PPE - intangibles) (USD) -35M 995,517 -65.3M -85.6M -63.4M -96.5M -84.6M 22.5M -51.1M -41.2M
Income detail
Research and development expense (USD) 33.1M 44.2M 72.7M 85.8M 107M 68.5M 70M 48.9M 55.9M 64.8M
↳ 5y CAGR +5.5% +17.8% +37.1% +51.6% +42.2% +15.7% +9.6% -7.6% -8.2% -9.5%
Total comprehensive income (USD) -44M -42.6M -90.7M -97.5M -62.2M -130M -93.5M -60.5M -40.3M -5.95M
Comprehensive income to owners (USD) -44M -42.6M -90.7M -97.5M -62.2M -130M -93.5M -60.5M -40.3M -5.95M
Reported Mar 8, 2018 Mar 8, 2018 May 9, 2019 Mar 4, 2020 Feb 25, 2021 Mar 11, 2022 Mar 22, 2023 Mar 20, 2025 Mar 20, 2025 Mar 19, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

– Initiated Phase 2 clinical study of ABI-6250 in patients with chronic hepatitis delta virus infection –

– Exercised 40% U.S. Profit-Share option for the HSV helicase primase inhibitor program –

– Received first $75 million collaboration extension fee from Gilead; cash runway projected into 2029 –

SOUTH SAN FRANCISCO, Calif. – November 12, 2026 – Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today reported financial results for the third quarter ended September 30, 2026, and recent business updates.

“This quarter, we rapidly advanced our liver disease program by initiating the Phase 2 study of ABI-6250 in chronic hepatitis delta virus and preparing for our Phase 2 study in cholestatic liver diseases, which we expect to begin in the first quarter next year,” said Jason Okazaki, chief executive officer and president of Assembly Bio. “Alongside that progress, we elected to share U.S. costs and profits for the HSV helicase primase inhibitor program under our collaboration with Gilead, a decision we believe represents a significant opportunity to build long-term value.

November 2, 2026 at 4:00 PM EST

PDF Version

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will present and participate in one-on-one meetings at the following upcoming investor conferences in November:

Guggenheim 3rdAnnual Healthcare Innovation Conference Date: Tuesday, November 10 Fireside chat: 2:00 PM ET

UBS Global Biopharma Conference Date: Monday, November 16 Fireside chat: 12:00 PM GMT

2026 Jefferies Global Healthcare Conference in London Date: Tuesday, November 17

Webcasts for the fireside chats will be available through the Events and Presentations section of Assembly Bio’s website at: https://investor.assemblybio.com/events-presentations. Replays will be accessible following the events.

About Assembly Biosciences Assembly Biosciences is a biotechnology company developing innovative small-molecule therapeutics aimed at advancing the treatment paradigm of serious viral and liver diseases and improving the lives of patients worldwide. Led by an accomplished leadership team in antiviral and liver disease drug development, Assembly Bio is committed to improving outcomes for people living with the chronic impacts of herpesviruses, hepatitis delta virus (HDV) infections, cholestatic liver diseases and hepatitis B virus (HBV). For more information, visit assemblybio.com.

Forward-Looking Statements The information in this press release contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to materially differ. These risks and uncertainties include: Assembly Bio’s ability to realize the potential benefits of its collaboration with Gilead, including all financial aspects of the collaboration and equity investments; Assembly Bio’s ability to initiate and complete clinical studies involving its therapeutic product candidates, including studies contemplated by Assembly Bio’s collaboration with Gilead, including studies conducted by Gilead, in the currently anticipated timeframes or at all; safety and efficacy data from clinical or nonclinical studies may not warrant further development of product candidates; clinical and nonclinical data may not differentiate product candidates from other companies’ candidates; Assembly Bio’s ability to maintain financial resources and secure additional funding necessary to continue its research activities, clinical studies, and other business operations; potential effects of changes in government regulation; results of nonclinical studies may not be representative of disease behavior in a clinical setting and may not be predictive of the outcomes of clinical studies; and other risks identified from time to time in Assembly Bio’s reports filed with the U.S. Securities and Exchange Commission (the SEC). You are urged to consider statements that include the words may, will, would, could, should, might, believes, hopes, estimates, projects, potential, expects, plans, anticipates, intends, continues, forecast, designed, goal or the negative of those words or other comparable words to be uncertain and forward-looking. Assembly Bio intends such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. More information about Assembly Bio’s risks and uncertainties are more fully detailed under the heading “Risk Factors” in Assembly Bio’s filings with the SEC, including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Except as required by law, Assembly Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

October 29, 2026 at 4:00 PM EDT

PDF Version

– Phase 2 study will evaluate the safety, pharmacokinetics and antiviral activity of ABI-6250 in participants with chronic HDV infection – – Initial data from the Phase 2 study is expected in the fourth quarter of 2027 –

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced dosing of the first two participants in a Phase 2 clinical study of ABI-6250, the company’s investigational oral small-molecule entry inhibitor candidate, in participants with chronic hepatitis delta virus (HDV) infection.

The Phase 2 study is expected to enroll approximately 80 participants with chronic HDV infection and will evaluate two once-daily oral dose levels of ABI-6250. The study will evaluate safety, pharmacokinetics, pharmacodynamics and efficacy, including changes from baseline in HDV RNA and alanine aminotransferase levels. Initial data from the study is expected in the fourth quarter of 2027.

Chronic HDV infection is the most severe form of viral hepatitis and results in more rapid progression to cirrhosis, liver cancer, decompensated liver disease or death than other forms of hepatitis. Treatment options remain limited, with only one approved therapy, a peptide inhibitor of sodium taurocholate cotransporting polypeptide (NTCP) that requires daily injections, underscoring the need for effective oral treatment options.

“Advancing ABI-6250 into Phase 2 represents an important milestone in our efforts to provide people living with chronic HDV infection a convenient, once-daily oral alternative to the currently available daily injectable therapy,” said Anuj Gaggar, MD, PhD, chief medical officer of Assembly Bio. “Supported by encouraging Phase 1a findings, this study will help evaluate the potential of ABI-6250 to deliver meaningful antiviral activity through a differentiated treatment approach.”

In the completed Phase 1a study in healthy participants, ABI-6250 demonstrated a safety and pharmacokinetic profile supporting advancement into Phase 2 development. ABI-6250 had a mean half-life of approximately four days, supporting once-daily oral dosing, and changes in serum bile acids were consistent with NTCP target engagement. The Phase 1a findings were supported by preclinical data demonstrating low nanomolar potency across multiple HDV genotypes in vitro and selectivity for NTCP versus other bile acid transporters.

Under Assembly Bio’s collaboration agreement with Gilead Sciences, Inc. (Gilead), Gilead has the right to obtain an exclusive license for further development and commercialization of ABI-6250 through completion of the Phase 2 study and delivery and review of the related option data package for a $90 million opt-in fee.

About the ABI-6250 Phase 2 Study

ABI-6250-201 is a multicenter, open-label Phase 2 clinical study expected to enroll approximately 80 participants with chronic HDV infection. In the main cohort, approximately 50 participants will receive a low or high dose of once-daily oral ABI-6250 or enter a delayed-treatment group. Following analysis of the main cohort’s Week 16 primary endpoint, a dose will be selected for an expansion cohort of approximately 20 to 30 additional participants. The expansion cohort is designed to provide additional safety data to support potential Phase 3 development.

The study will evaluate safety, pharmacokinetics, pharmacodynamics and antiviral activity, with key efficacy measures including changes from baseline in HDV RNA and alanine aminotransferase levels.

Additional information about the Phase 2 study is available at clinicaltrials.gov using the identifier NCT07762027.

About ABI-6250

ABI-6250 is an investigational first-in-class oral small-molecule inhibitor of the sodium taurocholate co-transporting polypeptide (NTCP), a membrane protein selectively expressed on hepatocytes that facilitates bile acid transport into hepatocytes and also serves as the receptor for hepatitis B virus (HBV) and hepatitis delta virus (HDV) to enter hepatocytes. Assembly Bio is developing ABI-6250 for the treatment of chronic HDV infection, where inhibition of NTCP blocks viral entry and represents a clinically validated therapeutic mechanism. ABI-6250 is also being evaluated in cholestatic liver diseases, such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), where bile acid accumulation in the liver drives liver inflammation and liver injury.

About the Assembly Bio-Gilead Collaboration

In October 2023, Assembly Bio and Gilead entered into a 12-year collaboration to advance the research and development of novel antiviral therapies. Under the collaboration, Gilead has an option to obtain exclusive rights to each of Assembly Bio’s current and future programs, and Assembly Bio is eligible to receive collaboration extension fees, option fees, milestone payments and royalties. Following Gilead’s exercise of an option, Assembly Bio has the right to elect to share profits and costs in the U.S., as well as certain co-promotion rights for future programs.

To date, Gilead has exercised its option for Assembly Bio’s helicase-primase inhibitor program for recurrent genital herpes, and Assembly Bio has elected to participate in a 40% U.S. cost and profit share for the program.

About Assembly Biosciences

Assembly Biosciences is a biotechnology company developing innovative small-molecule therapeutics aimed at advancing the treatment paradigm of serious viral and liver diseases and improving the lives of patients worldwide. Led by an accomplished leadership team in antiviral and liver disease drug development, Assembly Bio is committed to improving outcomes for people living with the chronic impacts of herpesviruses, hepatitis delta virus (HDV) infections, cholestatic liver diseases and hepatitis B virus (HBV). For more information, visit assemblybio.com.

Forward-Looking Statements

The information in this press release contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to materially differ. These risks and uncertainties include: Assembly Bio’s ability to realize the potential benefits of its collaboration with Gilead, including all financial aspects of the collaboration and equity investments; Assembly Bio’s ability to initiate and complete clinical studies involving its therapeutic product candidates, including studies contemplated by Assembly Bio’s collaboration with Gilead, including studies conducted by Gilead, in the currently anticipated timeframes or at all; safety and efficacy data from clinical or nonclinical studies may not warrant further development of product candidates; clinical and nonclinical data may not differentiate product candidates from other companies’ candidates; Assembly Bio’s ability to maintain financial resources and secure additional funding necessary to continue its research activities, clinical studies, and other business operations; potential effects of changes in government regulation; results of nonclinical studies may not be representative of disease behavior in a clinical setting and may not be predictive of the outcomes of clinical studies; and other risks identified from time to time in Assembly Bio’s reports filed with the U.S. Securities and Exchange Commission (the SEC). You are urged to consider statements that include the words may, will, would, could, should, might, believes, hopes, estimates, projects, potential, expects, plans, anticipates, intends, continues, forecast, designed, goal or the negative of those words or other comparable words to be uncertain and forward-looking. Assembly Bio intends such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. More information about Assembly Bio’s risks and uncertainties are more fully detailed under the heading “Risk Factors” in Assembly Bio’s filings with the SEC, including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Except as required by law, Assembly Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Prompts

Assembly Biosciences, Inc. (ticker ASMB), listed in United States.

Company History

Date Change Detail
Jul 14, 2014 Renamed VENTRUS BIOSCIENCES INC → ASSEMBLY BIOSCIENCES, INC.

ETFs Holding Assembly Biosciences, Inc.

ETF Weight in ETF Shares Market value As of
AVSC 0.01% 18,563 $ 395.206K Nov 16, 2026